FDA Accepts Label Expansion Application for Bristol-Myers and Merck's Anemia Therapy Reblozyl
Bristol-Myers Squibb, in collaboration with Merck, announced that the U.S. Food and Drug Administration (FDA) has accepted their application to expand the label of Reblozyl, an anemia treatment developed jointly by both companies. The FDA's acceptance follows a review process initiated after Bristol-Myers reported its Q2 2026 financial results. The expansion aims to broaden the approved use of Reblozyl for additional patient populations or conditions beyond those currently covered in its label, potentially increasing market access and revenue potential for both companies. The FDA's acceptance signals a positive step toward regulatory approval but does not guarantee final clearance at this stage.
